Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jupiter Neurosciences, Inc. ( (JUNS) ) just unveiled an update.
On December 19, 2025, Jupiter Neurosciences, Inc. held its annual meeting of stockholders, with a quorum of approximately 71.68% of its 34.4 million outstanding common shares represented in person or by proxy. Shareholders re-elected all seven director nominees to serve until the 2026 annual meeting, approved an amendment to increase authorized common shares from 125 million to 500 million, adopted the 2025 equity incentive plan, ratified Cherry Bekaert LLC as the independent auditor for the 2025 fiscal year, and approved, for Nasdaq compliance purposes, the potential issuance of more than 19.99% of outstanding shares in connection with up to $20 million of securities issuable under the Standby Equity Purchase Agreement with YA II PN, Ltd., signaling strong investor support for the company’s capital-raising flexibility and governance proposals.
The most recent analyst rating on (JUNS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jupiter Neurosciences, Inc. stock, see the JUNS Stock Forecast page.
More about Jupiter Neurosciences, Inc.
Average Trading Volume: 107,417
Technical Sentiment Signal: Sell
Current Market Cap: $37.87M
Learn more about JUNS stock on TipRanks’ Stock Analysis page.